A Study of the Intestinal Microbiome in Patients with Cirrhosis

NCT06808698•Yonsei University

Summary

This study aims to establish a cohort for analyzing the gut microbiome of patients with liver cirrhosis and to identify factors that influence the prognosis of these patients.

Eligibility

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Aged 19 years or older:
•2. Patients visiting the hospital with liver cirrhosis.
•3. Patients diagnosed with liver cirrhosis who can understand the information provided to them or their representatives and have voluntarily given written consent to participate in this study
•2. Patients who refuse participation
•3. Patients who have taken or been administered antibiotics within the past 2 weeks or are scheduled to take or receive antibiotics during the study period
•4. Cases where the diagnosis is unclear
•5. Cases with incomplete data or missing investigation items
•6. Individuals deemed unsuitable by the principal investigator for other reasons

Key Dates

Start Date

June 1, 2025

Primary Completion Date

December 1, 2025

Completion Date

December 1, 2025

Last Updated

February 5, 2025

Enrollment

100

ESTIMATED participants

Conditions

Liver Cirrhosis

Interventions

Determine the gut microbiome at baseline and 12 months.

OTHER

Contacts

Hye Won Professor Lee

CONTACT

+822-2228-0813 lorry-lee@yuhs.ac

Verification of Risk Factors of Thrombohemorrhagic Complications in Recipients After Related Liver Transplantation

NCT06169592

Liver CirrhosisLiver Transplant; Complications

View study

RECRUITING

Analysis of Methylomic Features and Prognostic Risk Prediction in Patients With Hepatitis B-related Acute-on-chronic Liver Failure

NCT07275554

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 5, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of the Intestinal Microbiome in Patients with Cirrhosis

Inclusion Criteria

Verification of Risk Factors of Thrombohemorrhagic Complications in Recipients After Related Liver Transplantation

Analysis of Methylomic Features and Prognostic Risk Prediction in Patients With Hepatitis B-related Acute-on-chronic Liver Failure

Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis

Stop of Proton-pump Inhibitor Treatment in Patients With Liver Cirrhosis - a Double-blind, Placebo-controlled Trial

DOAC in Patients with Child a or B Liver Cirrhosis

Role of Nutritional Intervention for the Treatment of Sarcopenia in Cirrhotic Patients with Refractory Ascites Candidate to Transjugular Intrahepatic Portosystemic Shunt Placement and Identification of Prognostic Factors Related to Clinical Outcome